CD38 and plasma cell myeloma: As a result, several strategies have been proposed to increase CD38 expression by myeloma cells in patients progressing on Daratumumab such as pharmacological intervention with ATRA or panobinostat or introduction of a treatment-free interval to allow for spontaneous recovery of CD38 expression with the hope of improving the response to treatment with Daratumumab [15,16].